Q-omics provides the consensus-scored MIRLET7F1 profile across patient tissues and cancer cell-line models. MIRLET7F1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIRLET7F1 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, MIRLET7F1 RNA expression shows 8,485 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, LUAD, and UVM as cancer lineages where MIRLET7F1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIRLET7F1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIRLET7F1 survival associations across molecular data types. MIRLET7F1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIRLET7F1 RNA expression–survival associations across cancer types. High MIRLET7F1 expression shows unfavorable associations in MESO, CESC, LIHC and UCEC, but favorable associations in BLCA and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIRLET7F1 RNA expression.
This table summarizes MIRLET7F1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIRLET7F1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIRLET7F1 shows lower tumor expression in LUAD, LUSC, BRCA, BLCA, KICH and KIRP. The LUAD box plot shows higher MIRLET7F1 RNA expression in normal versus tumor tissue (log2 FC = −1.038, t-test p < 0.001).
This table shows molecular features associated with MIRLET7F1 in patient tissues and cancer cell lines. In patient samples, MIRLET7F1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
